Embla Medical
Embla Medical, a leading name in the medical technology sector, is headquartered in Iceland (IS) and operates extensively across Europe and North America. Founded in 1998, the company has established itself as a pioneer in sleep diagnostics and respiratory care, offering innovative solutions that enhance patient outcomes. Embla Medical's core products include advanced sleep monitoring devices and software, which are distinguished by their accuracy and user-friendly design. The company has achieved significant milestones, including the development of cutting-edge polysomnography systems that cater to both clinical and home settings. With a strong market position, Embla Medical is recognised for its commitment to quality and innovation, making it a trusted partner for healthcare professionals worldwide.
DitchCarbon Score
How does Embla Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Embla Medical's score of 46 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Embla Medical's reported carbon emissions
Embla Medical hf, headquartered in Iceland, has set ambitious climate commitments to address its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established significant reduction targets through the Science Based Targets initiative (SBTi). Embla Medical is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050. The company has set near-term targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 79% by 2030, using 2019 as the baseline year. Additionally, it aims to cut absolute Scope 3 emissions—covering purchased goods and services, fuel and energy-related activities, and transportation—by 25% by 2030, with a 2021 baseline. For long-term goals, Embla Medical plans to reduce absolute Scope 1 and 2 emissions by 90% by 2050 and Scope 3 emissions by 90% by the same year. These targets align with the necessary reductions to limit global warming to 1.5°C, demonstrating the company's commitment to sustainable practices in the healthcare equipment and supplies sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Embla Medical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
